Stellato Claudia, Porreca Immacolata, Cuomo Danila, Tarallo Roberta, Nassa Giovanni, Ambrosino Concetta
Laboratory of Molecular Medicine and Genomics, Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy.
Biogem scarl, Ariano Irpino (AV), Italy.
Proteomics. 2016 Jan;16(2):288-300. doi: 10.1002/pmic.201500261. Epub 2015 Dec 17.
Understanding of the role of estrogen receptors (ERα and ERβ) in the pathophysiology of breast cancer (BC) has considerably increased in last decades. Despite sharing a similar structure, these two transcription factors often exert opposite roles in BC. In addition, it has been shown that their transcriptional activity is not strictly associated to ligand activation and that unliganded ERs are able to "have a life on their own." This appears to be mainly due to ligand-independent mechanisms leading to ERs PTMs or to their recruitment to specific protein complexes, dependent on cellular context. Furthermore, a significant unliganded ER activity, probably independent by the activation of other pathways, has been recently reported to affect gene transcription, microRNA expression, and downstream proteome. In this review, we describe recent findings on nuclear and cytoplasmic unliganded ERα and ERβ activity. We focus on functional genomics, epigenomics, and interaction proteomics data, including PTM induced by ERs-modulated miRNAs in the BC context. A better comprehension of the molecular events controlled by unliganded ERs activity in BC pathogenesis is crucial since it may impact the therapeutic approach to the initial or acquired resistance to endocrine therapies, frequently experienced in the treatment of BC.
在过去几十年中,对雌激素受体(ERα和ERβ)在乳腺癌(BC)病理生理学中作用的理解有了显著提高。尽管这两种转录因子结构相似,但它们在乳腺癌中常常发挥相反的作用。此外,研究表明它们的转录活性并不严格与配体激活相关,未结合配体的雌激素受体能够“独立发挥作用”。这似乎主要是由于导致雌激素受体发生翻译后修饰(PTM)或使其募集到特定蛋白质复合物的非配体依赖性机制,具体取决于细胞环境。此外,最近有报道称,一种显著的未结合配体的雌激素受体活性可能独立于其他途径的激活,会影响基因转录、微小RNA表达和下游蛋白质组。在本综述中,我们描述了关于细胞核和细胞质中未结合配体的ERα和ERβ活性的最新研究结果。我们重点关注功能基因组学、表观基因组学和相互作用蛋白质组学数据,包括在乳腺癌背景下由雌激素受体调节的微小RNA诱导的翻译后修饰。更好地理解未结合配体的雌激素受体活性在乳腺癌发病机制中所控制的分子事件至关重要,因为这可能会影响对乳腺癌治疗中经常出现的初始或获得性内分泌治疗耐药性的治疗方法。